Company Filing History:
Years Active: 2014-2015
Title: Kyeng-Jung Kim: Innovator in Pharmaceutical Composition and Angiogenesis Research
Introduction
Kyeng-Jung Kim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceutical compositions, particularly in the area of angiogenesis suppression and promotion. With a total of 2 patents, his work is paving the way for advancements in cancer treatment and wound healing.
Latest Patents
Kyeng-Jung Kim's latest patents include a pharmaceutical composition for suppressing angiogenesis, which contains heat shock protein 27 (HSP27) or a nucleic acid encoding HSP27. This invention aims to provide a method for treating cancer by utilizing HSP27. Additionally, he has developed a method for screening active materials that can suppress angiogenesis, which involves measuring the content of HSP27 in endothelial cell lines.
Another notable patent focuses on a pharmaceutical composition that promotes wound healing. This composition contains an antibody that specifically binds to HSP27 and is intended for treating various angiogenesis-dependent ailments, such as chronic ulcers and ischemic strokes. The method for promoting the growth of endothelial cells using this antibody further enhances the potential applications of his research.
Career Highlights
Kyeng-Jung Kim is affiliated with the Korea Institute of Radiological and Medical Sciences, where he conducts his research and development. His work has garnered attention for its innovative approach to addressing critical health issues related to angiogenesis.
Collaborations
He collaborates with notable colleagues, including Yoon Jin Lee and Yun-Sil Lee, to further enhance the impact of his research in the medical field.
Conclusion
Kyeng-Jung Kim's contributions to pharmaceutical compositions and angiogenesis research are significant. His innovative patents are set to make a lasting impact on cancer treatment and wound healing therapies.